$66 million in 10 years: groundbreaking strategic investment fund to drive biomedical innovation
66ten is a strategic investment fund that values scientific excellence and the potential for groundbreaking innovations. Operating as a pre-seed and seed fund enables 66ten to support a range of projects with commercial potential, from initial ideation to projects that have already progressed further in development.
66ten is structured into different investment streams to ensure the fund efficiently supports projects at different development stages. This strategy mitigates risk and streamlines the operation of the WEHI Ventures team.
Dr Anne-Laure Puaux, chief executive officer at WEHI Ventures and head of Business Development at WEHI, said that the institute has an established record of outstanding scientific discoveries.
“66ten was…
